MA40910A - Poudres de rapamycine pour administration pulmonaire - Google Patents

Poudres de rapamycine pour administration pulmonaire

Info

Publication number: MA40910A
Authority: MA; Morocco
Prior art keywords: rapamycin; powders; pulmonary administration; pulmonary; administration
Prior art date: 2014-11-07

Application number

MA040910A

Other languages

English (en)

Inventor

Abhijit Kamerkar

Michael M Lipp

Original Assignee

Civitas Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-07

Filing date

2015-11-05

Publication date

2017-09-12

2015-11-05 Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc

2017-09-12 Publication of MA40910A publication Critical patent/MA40910A/fr

Links

239000000843 powder Substances 0.000 title 1
230000002685 pulmonary effect Effects 0.000 title 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
229960002930 sirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

MA040910A 2014-11-07 2015-11-05 Poudres de rapamycine pour administration pulmonaire MA40910A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462076651P	2014-11-07	2014-11-07

Publications (1)

Publication Number	Publication Date
MA40910A true MA40910A (fr)	2017-09-12

Family

ID=54697649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA040910A MA40910A (fr)	2014-11-07	2015-11-05	Poudres de rapamycine pour administration pulmonaire

Country Status (8)

Country	Link
US (1)	US9387169B2 (fr)
EP (1)	EP3215121B1 (fr)
JP (2)	JP2017533212A (fr)
AU (2)	AU2015342919B2 (fr)
CA (1)	CA2966637C (fr)
ES (1)	ES3022184T3 (fr)
MA (1)	MA40910A (fr)
WO (1)	WO2016073836A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6529012B2 (ja)	2013-10-08	2019-06-12	エイアイ・セラピューティクス・インコーポレーテッド	リンパ脈管筋腫症の処置のためのラパマイシン
NZ724756A (en)	2014-04-04	2023-07-28	Ai Therapeutics Inc	An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru) *	2014-10-07	2020-09-24	ЭйАй ТЕРАПЬЮТИКС, ИНК.	Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
PT3429580T (pt) *	2016-03-16	2025-08-12	Buzzelet Development And Technologies Ltd	Composição de canabinoides enriquecida em terpenos
US20200230115A1 (en) *	2017-07-24	2020-07-23	University Of Cincinnati	Methods of treating influenza-associated viral pneumonia
US11878023B2 (en)	2017-10-25	2024-01-23	Arizona Board Of Regents On Behalf Of The University Of Arizona	Compositions and methods for delivering pharmaceutical agents

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5635161A (en)	1995-06-07	1997-06-03	Abbott Laboratories	Aerosol drug formulations containing vegetable oils
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9606452D0 (en)	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US6652837B1 (en)	1996-05-24	2003-11-25	Massachusetts Institute Of Technology	Preparation of novel particles for inhalation
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en)	1996-05-24	2001-02-13	Massachusetts Institute Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en)	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US20020052310A1 (en)	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US6451784B1 (en)	1996-12-30	2002-09-17	Battellepharma, Inc.	Formulation and method for treating neoplasms by inhalation
AU741439B2 (en)	1996-12-30	2001-11-29	Battelle Memorial Institute	Formulation and method for treating neoplasms by inhalation
CA2277801C (fr)	1997-01-16	2002-10-15	Massachusetts Institute Of Technology	Preparation de particules pour inhalation
US5989591A (en)	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
US7052678B2 (en)	1997-09-15	2006-05-30	Massachusetts Institute Of Technology	Particles for inhalation having sustained release properties
US20040039047A1 (en)	1998-08-11	2004-02-26	Mark Zamoyski	Compositions and methods for treating lung cancers
US6858199B1 (en)	2000-06-09	2005-02-22	Advanced Inhalation Research, Inc.	High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en)	1999-08-25	2003-07-01	Advanced Inhalation Research, Inc.	Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en)	1999-08-25	2007-08-07	Advanced Inhalation Research, Inc.	Use of simple amino acids to form porous particles
JP5698423B2 (ja) *	2000-06-27	2015-04-08	ベクトゥラ・リミテッド	医薬組成物で使用するための粒子の製造法
US20040018228A1 (en)	2000-11-06	2004-01-29	Afmedica, Inc.	Compositions and methods for reducing scar tissue formation
JP2005504715A (ja)	2000-12-29	2005-02-17	アドバンストインハレーションリサーチ，インコーポレイテッド	持続放出特性を有する吸入用粒子
US6766799B2 (en)	2001-04-16	2004-07-27	Advanced Inhalation Research, Inc.	Inhalation device
US6848197B2 (en)	2001-04-18	2005-02-01	Advanced Inhalation Research, Inc.	Control of process humidity to produce large, porous particles
US6793912B2 (en)	2001-08-20	2004-09-21	Transave Inc.	Treatment of cancers by inhalation of stable platinum-containing formulations
CA2456746A1 (fr)	2001-08-20	2003-02-27	Transave, Inc.	Procede destine a traiter des cancers du poumon
JP2005511629A (ja)	2001-11-20	2005-04-28	アドバンストインハレーションリサーチ，インコーポレイテッド	持続作用生成物送達用組成物
AU2002352836B2 (en)	2001-11-20	2005-09-29	Alkermes, Inc.	Improved particulate compositions for pulmonary delivery
AU2002334929C1 (en)	2002-03-20	2006-09-14	Advanced Inhalation Research, Inc.	Puncturing means for use in an inhalation device
AU2003218307B8 (en)	2002-03-20	2006-08-31	Alkermes, Inc.	Pulmonary delivery for levodopa
US7008644B2 (en)	2002-03-20	2006-03-07	Advanced Inhalation Research, Inc.	Method and apparatus for producing dry particles
US7754242B2 (en)	2002-03-20	2010-07-13	Alkermes, Inc.	Inhalable sustained therapeutic formulations
WO2003079885A2 (fr)	2002-03-20	2003-10-02	Advanced Inhalation Research, Inc.	Formulations therapeutiques soutenues respirables
EP1506032A1 (fr)	2002-05-20	2005-02-16	Research Development Foundation	Medicament de type aerosol pour l'inhibition de metastases pulmonaires
SI1531794T1 (sl)	2002-06-28	2017-12-29	Civitas Therapeteutics, Inc.	Epinefrin za vdihavanje
US7763280B2 (en)	2002-11-28	2010-07-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tiotropium containing powder formulation for inhalation
US20050119330A1 (en)	2003-03-17	2005-06-02	Kao Peter N.	Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7954491B2 (en)	2003-06-13	2011-06-07	Civitas Therapeutics, Inc.	Low dose pharmaceutical powders for inhalations
AR050374A1 (es)	2004-08-20	2006-10-18	Wyeth Corp	Forma polimorfica de rafampicina
MX2007003731A (es)	2004-09-29	2007-08-14	Johnson & Johnson	Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
BRPI0608573A2 (pt)	2005-03-08	2017-07-25	Lifecycle Pharma As	Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
MX2007011494A (es)	2005-03-17	2007-12-06	Elan Pharma Int Ltd	Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
US20070142422A1 (en)	2005-12-20	2007-06-21	Wyeth	Control of CCI-779 dosage form stability through control of drug substance impurities
KR20080090493A (ko)	2006-02-02	2008-10-08	노파르티스 아게	결절성 경화증의 치료
WO2008022256A2 (fr)	2006-08-16	2008-02-21	Blagosklonny Mikhail V	Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
US20080063722A1 (en)	2006-09-08	2008-03-13	Advanced Inhalation Research, Inc.	Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
EP2322235A1 (fr)	2006-11-20	2011-05-18	Lutonix, Inc.	Revêtements de libération de médicament pour dispositifs médicaux
EP1952807A1 (fr)	2007-01-24	2008-08-06	LEK Pharmaceuticals D.D.	Formulation de Sirolimus
US20100166869A1 (en) *	2007-05-03	2010-07-01	Desai Neil P	Methods and compositions for treating pulmonary hypertension
US8496002B2 (en)	2007-06-12	2013-07-30	Civitas Therapeutics, Inc.	Powder inhaler devices
US8614255B2 (en)	2007-08-21	2013-12-24	Civitas Therapeutics, Inc.	Pulmonary pharmaceutical formulations
GB0908129D0 (en)	2009-05-12	2009-06-24	Innovata Ltd	Composition
AU2010253578B2 (en) *	2009-05-27	2014-01-30	Samyang Biopharmaceuticals Corporation	A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
US9248110B2 (en)	2010-03-18	2016-02-02	Steven Lehrer	Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt)	2010-04-21	2013-04-17	Hovione Farmaciencia S A	Processo para processamento de partículas de ingredientes activos farmacêuticos
WO2011163600A2 (fr)	2010-06-25	2011-12-29	Apt Pharmaceuticals, Inc.	Compositions de tacrolimus pour administration par aérosol
BR112015010601B1 (pt) *	2012-11-09	2022-07-19	Civitas Therapeutics, Inc.	Composição farmacêutica e uso da composição
US8545878B1 (en) *	2012-11-09	2013-10-01	Civitas Therapeutics, Inc.	Capsules containing high doses of levodopa for pulmonary use
JP6529012B2 (ja) *	2013-10-08	2019-06-12	エイアイ・セラピューティクス・インコーポレーテッド	リンパ脈管筋腫症の処置のためのラパマイシン
MX2016010373A (es) *	2014-02-11	2016-11-30	Lam Therapeutics Inc	Rapamicina para el tratamiento de linfangioleiomiomatosis.
NZ724756A (en) *	2014-04-04	2023-07-28	Ai Therapeutics Inc	An inhalable rapamycin formulation for treating age-related conditions

2015
- 2015-11-05 MA MA040910A patent/MA40910A/fr unknown
- 2015-11-06 JP JP2017522659A patent/JP2017533212A/ja active Pending
- 2015-11-06 EP EP15798604.3A patent/EP3215121B1/fr active Active
- 2015-11-06 CA CA2966637A patent/CA2966637C/fr active Active
- 2015-11-06 AU AU2015342919A patent/AU2015342919B2/en active Active
- 2015-11-06 WO PCT/US2015/059429 patent/WO2016073836A1/fr not_active Ceased
- 2015-11-06 US US14/934,491 patent/US9387169B2/en active Active
- 2015-11-06 ES ES15798604T patent/ES3022184T3/es active Active
2020
- 2020-10-06 AU AU2020250195A patent/AU2020250195B2/en active Active
2021
- 2021-01-15 JP JP2021004679A patent/JP7277490B2/ja active Active

Also Published As

Publication number	Publication date
JP2021054870A (ja)	2021-04-08
WO2016073836A1 (fr)	2016-05-12
JP7277490B2 (ja)	2023-05-19
CA2966637C (fr)	2024-02-13
ES3022184T3 (en)	2025-05-28
US9387169B2 (en)	2016-07-12
NZ731431A (en)	2024-07-05
AU2020250195A1 (en)	2020-11-05
US20160128936A1 (en)	2016-05-12
AU2015342919B2 (en)	2020-07-23
AU2020250195B2 (en)	2022-06-02
CA2966637A1 (fr)	2016-05-12
EP3215121A1 (fr)	2017-09-13
EP3215121B1 (fr)	2025-02-26
EP3215121C0 (fr)	2025-02-26
JP2017533212A (ja)	2017-11-09
AU2015342919A1 (en)	2017-05-18

Publication	Publication Date	Title
SG11201706123XA (en)	2017-08-30	Pharmaceutical compositions comprising meloxicam
MA41265A (fr)	2017-10-31	Compositions pour administration de médicaments iléo-jéjunal.
GB201419257D0 (en)	2014-12-10	Pharmaceutical compositions
GB201618482D0 (en)	2016-12-14	Pharmaceutical compositions
GB201409471D0 (en)	2014-07-09	Pharmaceutical composition
IL249553A0 (en)	2017-02-28	Pharmaceutical preparations
GB201409488D0 (en)	2014-07-09	Pharmaceutical composition
GB201409485D0 (en)	2014-07-09	Pharmaceutical composition
GB201521462D0 (en)	2016-01-20	Pharmaceutical composition
DK3191085T3 (da)	2021-06-28	Misbrugsresistente farmaceutiske sammensætninger
IL251337A0 (en)	2017-05-29	Pharmaceutical preparations with long-term activity
MA40910A (fr)	2017-09-12	Poudres de rapamycine pour administration pulmonaire
SG11201705543VA (en)	2017-08-30	Sulfonamide pharmaceutical composition
ZA201508726B (en)	2017-03-29	Pharmaceutical composition
ZA201502073B (en)	2016-03-30	Pharmaceutical composition
IL255510A (en)	2018-04-30	Pharmaceutical compositions
IL250817A0 (en)	2017-04-30	pharmaceutical preparations
GB201515310D0 (en)	2015-10-14	Pharmaceutical composition
PL3389638T3 (pl)	2024-04-08	Kompozycja farmaceutyczna zawierająca pimobendan
GB201520862D0 (en)	2016-01-13	Pharmaceutical composition
SI3089740T1 (sl)	2020-09-30	Farmacevtski sestavek
SG11201608123VA (en)	2016-11-29	Pharmaceutical composition for external use
SG10201504332VA (en)	2016-01-28	Pharmaceutical Composition
PL3160263T3 (pl)	2022-01-17	Kompozycje do zapobiegania zakażeniom
SG11201608124XA (en)	2016-11-29	Pharmaceutical composition for external use